These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24415983)

  • 21. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
    Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
    Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
    Jerusalem G; Rorive A; Collignon J
    Breast Cancer (Dove Med Press); 2014; 6():43-57. PubMed ID: 24833916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
    Beck JT
    Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
    Arena F
    Cancer Manag Res; 2014; 6():389-95. PubMed ID: 25336989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
    Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
    Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
    Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
    Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
    J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
    Peterson ME
    Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
    Kümler I; Knoop AS; Jessing CA; Ejlertsen B; Nielsen DL
    ESMO Open; 2016; 1(4):e000062. PubMed ID: 27843622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
    Divers J; O'Shaughnessy J
    Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
    Jerusalem G; Rorive A; Collignon J
    Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
    Ciruelos E; Jerusalem G; Martin M; Tjan-Heijnen VCG; Neven P; Gavila J; Montemurro F; Generali D; Lang I; Martínez-Serrano MJ; Perelló MF; Conte P
    Clin Transl Oncol; 2020 Oct; 22(10):1857-1866. PubMed ID: 32170637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
    Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
    JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
    Beck JT; Mantooth R
    Case Rep Oncol; 2015; 8(1):101-5. PubMed ID: 25848360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.